title: Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin.
abstract: Most tumors, including gliomas, are resistant to tumor necrosis factor (TNF) cytotoxicity unless protein or RNA synthesis is inhibited. We investigated the effects of the combined use of TNF-alpha and cisplatin (CDDP) on cultured malignant glioma cells, T98G, U373MG, A172, and U87MG. All glioma cell lines were sensitive to treatment with CDDP but resistant to TNF-alpha during 24 h-incubation. The combined use of CDDP and TNF-alpha had synergistic effects on T98G and U87MG but not on U373MG and A172 cells. Sequential treatments showed that only pretreatment with CDDP for 2 h followed by TNF-alpha for 22 h was synergistic on cell cytotoxicity. Annexin V-flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling assay showed that TNF-alpha can induce apoptosis in cells treated with CDDP. Although only sensitive cell lines express transcripts for p75 TNF receptor 2, changes in TNF receptors were not found to contribute to the susceptibility to TNF-alpha. The production of interleukin-6, a representative cytoprotective cytokine, from glioma cells stimulated by TNF-alpha was suppressed by the combined use of actinomycin D, but not CDDP. Our results indicate that CDDP can sensitize glioma cells to TNF-alpha-induced apoptosis by a mechanism other than blocking the cytoprotective protein production.
authors.affiliation: Department of Neurosurgery, Graduate School, Tokyo Medical and Dental University, Japan.
authors.forename: L
authors.initials: L
authors.lastname: Duan
authors.forename: M
authors.initials: M
authors.lastname: Aoyagi
authors.forename: M
authors.initials: M
authors.lastname: Tamaki
authors.forename: K
authors.initials: K
authors.lastname: Nakagawa
authors.forename: G
authors.initials: G
authors.lastname: Nagashima
authors.forename: Y
authors.initials: Y
authors.lastname: Nagasaka
authors.forename: K
authors.initials: K
authors.lastname: Ohno
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D002945:Cisplatin / Q000494:pharmacology*; D004357:Drug Synergism; D005910:Glioma / Q000503:physiopathology*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D002945:Cisplatin